Natalia Barbara Kapelan

Ms. Natalia Barbara Kapelan

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2026 in Cells
Verified
Journal Article
Open access
PDF file
ARAdrianna Rutkowska
Adrianna Rutkowska
TSTadeusz Strózik
Tadeusz Strózik
TWTomasz Michał Wasiak
Tomasz Michał Wasiak
DCDamian Ciunowicz
Damian Ciunowicz
NKNatalia Barbara Kapelan
Natalia Barbara Kapelan
ESEwelina Anna Stoczynska-Fidelus
Ewelina Anna Stoczynska-Fidelus
CRISPR–Cas9 has progressed from an experimental tool to a therapeutic modality, marked by the first regulatory approvals of an ex vivo-edited autologous CD34+ hematopoietic stem cell product that induces fetal hemoglobin (CASGEVY/exa-cel). In this narrative review, we synthesize modality-specific molecular diagnostic strategies used across early CRISPR clinical translation. In parallel, early clinical experience has begun to demonstrate the feasibility of in vivo editing, including subretinal delivery for CEP290-associated inherited retinal degeneration (EDIT-101 programme) and hepatocyte-targeted lipid nanoparticles (LNPs) for liver-derived targets such as transthyretin and plasma prekallikrein (KLKB1). As translation expands across hematologic, metabolic, ocular and oncology indications, development is increasingly constrained by the predictability and safety of editing outcomes, delivery-determined biodistribution and exposure time, and immune recognition of bacterial Cas9 orthologs and delivery components. We summarize diagnostic readouts for confirming patient genotype, quantifying on-target editing and expression changes, assessing off-target and structural outcomes using orthogonal assays, and monitoring clonal dynamics and immune responses during long-term follow-up. We also discuss how these readouts interface with CMC controls and regulatory expectations for advanced therapy medicinal products (ATMPs), highlighting the need for fit-for-purpose, standardized testing frameworks in early trials.

13 October 2026 in Diabetology
Verified
Journal Article
Open access
PDF file
NKNatalia Barbara Kapelan
Natalia Barbara Kapelan
PTPiotr Tust
Piotr Tust
SSSebastian Skoczylas
Sebastian Skoczylas
TPTomasz Płoszaj
Tomasz Płoszaj
KGKarolina Gadzalska
Karolina Gadzalska
AZAgnieszka Zmysłowska
Agnieszka Zmysłowska
Background: ABCC8 gene variants have been linked to a range of conditions that affect insulin secretion, such as congenital hyperinsulinism, neonatal diabetes and maturity-onset diabetes of the young (MODY). This study aimed to characterise ABCC8 variants and to assess their relationship with clinical phenotypes and family segregation. Methods: Between 2017 and May 2026, tNGS (targeted next-generation sequencing) analysis was performed on the DNA of 1202 patients who were referred for suspected monogenic diabetes. The exons and flanking intronic regions of the ABCC8 gene were assessed for single nucleotide variants (SNVs) and small insertions and deletions (indels). Rare variants were prioritised based on population frequency, in silico predictions and clinical classification. Selected variants were confirmed, and segregation analysis was performed using Sanger sequencing. Results: We identified five patients carrying pathogenic or likely pathogenic ABCC8 variants. A frameshift ABCC8 variant had not been previously reported. All patients had diabetes, with some also presenting with a history of hypoglycaemia. Family studies also revealed intra-familial variability and enabled the identification of previously unrecognized affected relatives. Conclusions: Our findings support the broad clinical spectrum associated with ABCC8 variants and highlight the importance of family segregation analysis. Comprehensive molecular and clinical evaluation may improve the detection of patients with ABCC8-related diabetes and distinguish this condition from other forms of monogenic diabetes.